Welcome to our dedicated page for VTEX SEC filings (Ticker: VTEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VTEX filings document the reporting framework of a foreign private issuer whose common shares trade on the NYSE and whose business is a SaaS commerce platform for brands and retailers. Form 6-K reports include interim condensed consolidated financial statements, management discussion and analysis, U.S. GAAP operating results, GMV, subscription revenue, non-GAAP measures, cash flow and customer or platform updates.
Annual and governance disclosures include Form 20-F availability, audited financial statements, risk and business disclosures, and proxy materials for annual general meeting votes. The filing record also describes the company's Class A and Class B common shares, auditor appointment matters, shareholder voting mechanics and the capital structure used to report equity, liquidity, marketable securities, trade receivables and deferred commissions.
VTEX reported Q3 results showing steady top-line growth and stronger profitability. Total revenue was $59.6 million (up 6.5% year over year), driven by higher transaction activity as GMV reached $5.0 billion (up 13.1%). Subscription revenue rose to $58.4 million, while services revenue declined to $1.2 million as the company phased out hyper-care implementations.
Gross profit increased to $46.1 million, lifting gross margin to 77.3% from 74.4%, helped by efficiencies in support. Operating income improved to $4.2 million and net income doubled to $6.4 million, with diluted EPS of $0.034. Year to date, operating cash flow strengthened to $22.1 million, aided by lower receivables. The company executed a share repurchase of $37.8 million year to date and subsequently canceled 1,817,461 Class A shares in October. R&D expense increased as VTEX invested in product and IT, while G&A and S&M were stable.
Cash and cash equivalents were $20.4 million and marketable securities $182.1 million as of September 30, 2025, supporting continued investment and operations.
VTEX reported Q3 results showing steady top-line growth and stronger profitability. Total revenue was $59.6 million (up 6.5% year over year), driven by higher transaction activity as GMV reached $5.0 billion (up 13.1%). Subscription revenue rose to $58.4 million, while services revenue declined to $1.2 million as the company phased out hyper-care implementations.
Gross profit increased to $46.1 million, lifting gross margin to 77.3% from 74.4%, helped by efficiencies in support. Operating income improved to $4.2 million and net income doubled to $6.4 million, with diluted EPS of $0.034. Year to date, operating cash flow strengthened to $22.1 million, aided by lower receivables. The company executed a share repurchase of $37.8 million year to date and subsequently canceled 1,817,461 Class A shares in October. R&D expense increased as VTEX invested in product and IT, while G&A and S&M were stable.
Cash and cash equivalents were $20.4 million and marketable securities $182.1 million as of September 30, 2025, supporting continued investment and operations.
VTEX (NYSE: VTEX) reported Q3 2025 results with GMV of US$5.0 billion (up 13.1% YoY) and total revenue of US$59.6 million (up 6.5%). Subscription revenue was US$58.4 million, 98% of total, rising 8.4%. Profitability improved: non-GAAP subscription gross margin reached 80.2%, non-GAAP income from operations was US$9.5 million (16% margin), and non-GAAP net income was US$10.6 million (18% margin). Non-GAAP free cash flow was US$7.5 million.
The company reduced headcount to 1,234 as of September 30, 2025. VTEX repurchased 4.5 million Class A shares at an average US$4.14 for US$18.8 million, bringing cumulative buybacks to 20.5 million shares for US$96.6 million. For Q4 2025, VTEX targets FX-neutral subscription revenue growth of 5.0%–10.0% (implying US$65.8–US$68.8 million), with a non-GAAP income from operations margin in the mid‑twenties and free cash flow margin in the high‑teens. For full-year 2025, VTEX targets FX-neutral subscription revenue growth of 9.3%–10.7% (implying US$234–US$237 million).
VTEX (NYSE: VTEX) reported Q3 2025 results with GMV of US$5.0 billion (up 13.1% YoY) and total revenue of US$59.6 million (up 6.5%). Subscription revenue was US$58.4 million, 98% of total, rising 8.4%. Profitability improved: non-GAAP subscription gross margin reached 80.2%, non-GAAP income from operations was US$9.5 million (16% margin), and non-GAAP net income was US$10.6 million (18% margin). Non-GAAP free cash flow was US$7.5 million.
The company reduced headcount to 1,234 as of September 30, 2025. VTEX repurchased 4.5 million Class A shares at an average US$4.14 for US$18.8 million, bringing cumulative buybacks to 20.5 million shares for US$96.6 million. For Q4 2025, VTEX targets FX-neutral subscription revenue growth of 5.0%–10.0% (implying US$65.8–US$68.8 million), with a non-GAAP income from operations margin in the mid‑twenties and free cash flow margin in the high‑teens. For full-year 2025, VTEX targets FX-neutral subscription revenue growth of 9.3%–10.7% (implying US$234–US$237 million).
VTEX Form 144 notice: The filer proposes to sell 4,500 shares of VTEX common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $18,630.00. The securities were acquired on 03/19/2019 through previously exercised stock options and were paid for in cash.
The filing shows the approximate date of sale as 09/16/2025 on the NYSE. Recent related transactions disclosed include multiple Rule 10b5-1 sales during July and August 2025 totaling 9,000 shares with gross proceeds reported for each sale.
VTEX Form 144 notice: The filer proposes to sell 4,500 shares of VTEX common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $18,630.00. The securities were acquired on 03/19/2019 through previously exercised stock options and were paid for in cash.
The filing shows the approximate date of sale as 09/16/2025 on the NYSE. Recent related transactions disclosed include multiple Rule 10b5-1 sales during July and August 2025 totaling 9,000 shares with gross proceeds reported for each sale.
Form 144 notice for VTEX (VTEX) indicates a proposed sale of 4,500 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $18,630.00 and an approximate sale date of 09/16/2025. The shares were acquired on 03/19/2019 by previously exercised stock options and paid in cash. The filing lists prior 10b5-1 plan sales by related parties totaling 9,000 shares in July and August 2025 with accompanying gross proceeds shown. The notice includes the standard Rule 144 representation about material nonpublic information and 10b5-1 plan adoption disclosure.
Form 144 notice for VTEX (VTEX) indicates a proposed sale of 4,500 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $18,630.00 and an approximate sale date of 09/16/2025. The shares were acquired on 03/19/2019 by previously exercised stock options and paid in cash. The filing lists prior 10b5-1 plan sales by related parties totaling 9,000 shares in July and August 2025 with accompanying gross proceeds shown. The notice includes the standard Rule 144 representation about material nonpublic information and 10b5-1 plan adoption disclosure.
VTEX Form 144 summary reports a proposed sale of 65,489 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $282,257.59. The securities were acquired as Restricted Stock Units from the issuer on 10/25/2021 and the planned approximate sale date is shown as 08/11/2025 on the NYSE.
The filing also lists 14 prior trades executed under a 10b5-1 plan between 05/12/2025 and 08/06/2025, totaling 104,426 shares sold, and shows 103,947,244 shares outstanding. The filer certifies they do not possess undisclosed material adverse information at the plan adoption or instruction date.
VTEX filed a Form 144 notifying the market of a proposed sale of 65,489 common shares with an aggregate market value of $282,257.59. The sale is scheduled to occur on 08/11/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The filing shows these shares were originally acquired as founders shares on 10/25/2019 and reports the issuer has 103,947,244 shares outstanding, making this a disclosure of an insider sale.
The Form also lists multiple recent 10b5-1 sales by "SIGNO INV TECH CO LTD" between May and August 2025 (including sales of 100; 6,250; and several 8,173-share transactions), indicating ongoing plan-based dispositions. The filing does not provide a date for adoption of any 10b5-1 plan or a stated reason for the proposed sale.